XML 27 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 01, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Trading Symbol TALS    
Entity Registrant Name TALARIS THERAPEUTICS, INC.    
Entity Central Index Key 0001827506    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Common Stock, Shares Outstanding   41,455,477  
Entity Current Reporting Status Yes    
Entity Shell Company false    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
Entity Interactive Data Current Yes    
Entity File Number 001-40384    
Entity Tax Identification Number 83-2377352    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 570 S. Preston St    
Entity Address, City or Town Louisville    
Entity Address, State or Province KY    
Entity Address, Postal Zip Code 40202    
City Area Code 502    
Local Phone Number 398-9250    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 280,469,780
Auditor Name Deloitte & Touche LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 34    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant’s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.